Who are Foradil P 24µg's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Salmeterol 50 mcg via DISKUS, indacaterol maleate/mometasone furoate, Spiromax Budesonide/formoterol, long-acting beta2-agonist, Salmeterol/Fluticasone propionate combination product, levalbuterol tartrate MDI.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/foradil-p-24-g.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Foradil P 24µg — Competitive Intelligence Brief

Foradil P 24µg (Foradil P 24µg) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: LABA. Area: Respiratory.

phase 2 LABA beta2-adrenergic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Foradil P 24µg (Foradil P 24µg) — MEDA Pharma GmbH & Co. KG. Foradil P 24µg is a long-acting beta2-adrenergic receptor agonist (LABA) used to control and prevent bronchospasm in patients with asthma and COPD.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Foradil P 24µg TARGET	Foradil P 24µg	MEDA Pharma GmbH & Co. KG	phase 2	LABA	beta2-adrenergic receptor
Salmeterol 50 mcg via DISKUS	Salmeterol 50 mcg via DISKUS	GlaxoSmithKline	marketed	Long-acting beta2-adrenergic agonist (LABA)	Beta2-adrenergic receptors
indacaterol maleate/mometasone furoate	indacaterol maleate/mometasone furoate	Novartis	phase 3	Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination	beta2-adrenergic receptor
Spiromax Budesonide/formoterol	Spiromax Budesonide/formoterol	University Medical Center Groningen	phase 3	Corticosteroid/long-acting beta2-adrenergic receptor agonist	Beta2-adrenergic receptor
long-acting beta2-agonist	long-acting beta2-agonist	National Heart, Lung, and Blood Institute (NHLBI)	phase 3	Long-acting beta2-agonist (LABA)	Beta2-adrenergic receptor
Salmeterol/Fluticasone propionate combination product	Salmeterol/Fluticasone propionate combination product	GlaxoSmithKline	phase 3	Long-acting beta2-adrenergic receptor agonist/inhaled corticosteroid combination	Beta2-adrenergic receptor
levalbuterol tartrate MDI	levalbuterol tartrate MDI	Sumitomo Pharma America, Inc.	phase 3	Long-acting beta2-adrenergic receptor agonist	beta2-adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (LABA class)

MEDA Pharma GmbH & Co. KG · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Foradil P 24µg — Competitive Intelligence Brief. https://druglandscape.com/ci/foradil-p-24-g. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab